BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Cassava 10K Filing Warns of Anticipated Hold, Paints Dire Picture of Alzheimer’s Space

  The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.

  March 3, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Sanofi, AstraZeneca Express Optimism Over Phase III Infant Respiratory Syncytial Virus Results

  In the Phase III MELODY trial, researchers found a 74.5% lower incidence of respiratory syncytial virus-caused pneumonia, and bronchiolitis. Here’s more about it.

  March 3, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Lone Star Bio

  CRISPR-Cas9 Redesign Reduces Mismatches, Potentially Improving Safety

  Researchers at the University of Texas at Austin shared results showing that their redesign of Cas9 makes it 4,000 times less likely to target the wrong stretch of DNA while still maintaining its efficiency.

  March 3, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  With New Funds, Foresite’s Bajaj Outlines Coming Life Sciences Transformation

  Foresite Labs CEO Vikram Bajaj believes that data science will fundamentally transform the life sciences and translate into the development of new therapeutics for various disease states.

  March 3, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Healx’s AI Platform Draws Novel Connections in Myriad Rare Diseases

  Healx brings the power of artifical intelligence (AI) to rare disease research with an ultimate focus on improving patient outcomes.

  March 3, 2022

   · 

  4 min read

   · 

  Abbey Glasure
• 

  Drug Development

  Biopharma Companies Move Forward with Clinical Research for Rare Diseases

  Fulcrum Therapeutics will launch a Phase III study of losmapimod in people with facioscapulohumeral muscular dystrophy later this year. Tonix wins Orphan Drug designation for Prader-Willi asset.

  March 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Roche Plans Ambitious Phase III Alzheimer’s Study

  The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.

  March 3, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Business

  Cancer Immunotherapy Market Expected to Exceed $34B by 2030

  A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.

  March 3, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Layoffs at Biogen Begin as Aduhelm Rollout Continues to Disappoint

  After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.

  March 3, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Life Sciences Industry Condemns Russian Invasion, Responds Accordingly

  On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.

  March 3, 2022

   · 

  3 min read

   · 

  Alex Keown